Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 13/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 14/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 14/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22058860 | 0.83 | OPRM1 (0.50) | OPRM1OPRD1OPRK1LMNAPDE4D | |
| SCHEMBL18473431 | 0.83 | OPRM1 (0.38) | OPRM1OPRD1OPRK1LMNAPDE4D | |
| SCHEMBL22058801 | 0.82 | OPRM1 (0.47) | OPRM1OPRD1OPRK1LMNAPDE4D | |
| SCHEMBL22058337 | 0.82 | OPRM1 (0.51) | OPRM1OPRD1OPRK1LMNAPDE4D | |
| SCHEMBL22058988 | 0.74 | OPRM1 (0.49) | OPRM1OPRD1OPRK1LMNAPDE4D | |
| SCHEMBL20170876 | 0.74 | OPRM1 (0.36) | OPRM1OPRD1OPRK1LMNAPDE4D | |
| SCHEMBL12646221 | 0.73 | OPRD1 (0.48) | OPRM1OPRD1OPRK1LMNAPDE4D | |
| SCHEMBL17284782 | 0.73 | OPRD1 (0.48) | OPRM1OPRD1OPRK1LMNAPDE4D | |
| SCHEMBL22058341 | 0.73 | OPRD1 (0.48) | OPRM1OPRD1OPRK1LMNAPDE4D | |
| SCHEMBL18473433 | 0.73 | OPRD1 (0.48) | OPRM1OPRD1OPRK1LMNAPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11142502-B2 | (+)-morphinans as antagonists of Toll-like receptor 9 and therapeutic uses thereof | MALLINCKRODT LLC (US) | 2021-10-12 | — | — | US | disclosed |
| US-20200172488-A1 | (+)-MORPHINANS AS ANTAGONISTS OF TOLL-LIKE RECEPTOR 9 AND THERAPEUTIC USES THEREOF | MALLINCKRODT LLC | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11142502-B2 | (+)-morphinans as antagonists of Toll-like receptor 9 and therapeutic uses thereof | TLR9, TLR3, TLR7 | OPRM1 5/4885OPRD1 13/4885OPRK1 11/4885 |
| US-20200172488-A1 | (+)-MORPHINANS AS ANTAGONISTS OF TOLL-LIKE RECEPTOR 9 AND THERAPEUTIC USES THEREOF | TLR9, TLR3, TLR7 | OPRM1 5/4885OPRD1 13/4885OPRK1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.